Related Experiment Video
Updated: Oct 19, 2026

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
Published on: April 5, 2017
Utilization of the CRISPR-Cas system for investigating tuberculosis drug resistance
Yanhui Yuan1,2,3, Jiahui Deng1,2,3, Xiang Li1,2,3
1School of Public Health, Hunan Normal University, Changsha, 410013, Hunan, PR China.
Abstract:
Drug-resistant tuberculosis(TB) presents a significant challenge to global efforts to control the disease. Addressing this issue requires a comprehensive understanding of drug resistance in Mycobacterium tuberculosis (M.tb). The clustered regularly interspaced short palindromic repeat (CRISPR) and CRISPR-associated protein (Cas) system are efficient genome-editing tools for various organisms and have facilitated new research directions regarding drug resistance in M.tb. This review summarizes recent progress in applying CRISPR/Cas technology to investigate drug resistance mechanisms in M.tuberculosis and discusses the potential of the CRISPR/Cas system as an integrated platform to transform research paradigms and enhance understanding of M.tuberculosis drug resistance mechanisms.
Related Concept Videos
CRISPR/Cas9 Genome Editing
CRISPR
CRISPR and crRNAs
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...